---
figid: PMC6996902__oncotarget-11-480-g001
figlink: pmc/articles/PMC6996902/figure/F1/
number: Figure 1
caption: 'The complex process of osteoclastogenesis in cancer is regulated by an interaction
  between bone, immune and cancer cells. Cancer cells promote this process in two
  ways: 1) indirectly, stimulating osteoblast to activate the RankL/Rank pathway (bone
  osteoclastogenesis) and deregulating immune cells activity against osteoclasts;
  2) directly, stimulating osteoclastsogenesis by upregulation of IL-1, IL-6, PTHrP,
  GM-CSF. After cancer cells signals, immune system cells activate osteoclastogenesis
  by upregulation of TNFa, IL-1a, IL-1b, IL-7, IL-8, IL-23. Once activated, osteoclasts
  protect their growth with the inactivation of immune system by TGF-beta production.
  Bisphosphonates (i.e. Zoledronic Acid) inhibit osteoclast formation, recruitment
  and adhesion to bone shift the balance towards OPG production by osteoblasts and
  induce osteoclasts apoptosis. Denosumab is a fully human monoclonal antibody with
  anti-RANKL activity, thus inhibiting osteoclast activation by Rank receptor. Initial
  data evidenced a possible role in immune system preservation by B cell/T cell differentiation
  and dendritic cell survival.'
pmcid: PMC6996902
papertitle: 'Immune system and bone microenvironment: rationale for targeted cancer
  therapies.'
reftext: Antonio Gnoni, et al. Oncotarget. 2020 Jan 28;11(4):480-487.
pmc_ranked_result_index: '45476'
pathway_score: 0.9677377
filename: oncotarget-11-480-g001.jpg
figtitle: 'Immune system and bone microenvironment: rationale for targeted cancer
  therapies'
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6996902__oncotarget-11-480-g001.html
  '@type': Dataset
  description: 'The complex process of osteoclastogenesis in cancer is regulated by
    an interaction between bone, immune and cancer cells. Cancer cells promote this
    process in two ways: 1) indirectly, stimulating osteoblast to activate the RankL/Rank
    pathway (bone osteoclastogenesis) and deregulating immune cells activity against
    osteoclasts; 2) directly, stimulating osteoclastsogenesis by upregulation of IL-1,
    IL-6, PTHrP, GM-CSF. After cancer cells signals, immune system cells activate
    osteoclastogenesis by upregulation of TNFa, IL-1a, IL-1b, IL-7, IL-8, IL-23. Once
    activated, osteoclasts protect their growth with the inactivation of immune system
    by TGF-beta production. Bisphosphonates (i.e. Zoledronic Acid) inhibit osteoclast
    formation, recruitment and adhesion to bone shift the balance towards OPG production
    by osteoblasts and induce osteoclasts apoptosis. Denosumab is a fully human monoclonal
    antibody with anti-RANKL activity, thus inhibiting osteoclast activation by Rank
    receptor. Initial data evidenced a possible role in immune system preservation
    by B cell/T cell differentiation and dendritic cell survival.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IL6
  - IL1A
  - IL1B
  - CSF2
  - TNFRSF11A
  - TNF
  - IL23A
  - CXCL8
  - IL7
  - TNFRSF11B
  - TNFSF11
  - Zoledronic acid
genes:
- word: PTHPP,IL-1,IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: PTHPP,IL-1,IL-6
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1A
  entrez: '3552'
- word: PTHPP,IL-1,IL-6
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: IL-1,
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1A
  entrez: '3552'
- word: IL-1,
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: GM-CSF
  symbol: GM-CSF
  source: hgnc_alias_symbol
  hgnc_symbol: CSF2
  entrez: '1437'
- word: Rank
  symbol: RANK
  source: hgnc_alias_symbol
  hgnc_symbol: TNFRSF11A
  entrez: '8792'
- word: IL-1b,
  symbol: IL-1B
  source: hgnc_alias_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: TNFA,IL-ia,IL-1b,
  symbol: TNFA
  source: hgnc_prev_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: TNFA,IL-ia,IL-1b,
  symbol: IL-1B
  source: hgnc_alias_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: TNFA,
  symbol: TNFA
  source: hgnc_prev_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: IL-23
  symbol: IL-23
  source: hgnc_alias_symbol
  hgnc_symbol: IL23A
  entrez: '51561'
- word: IL-8,
  symbol: IL-8
  source: hgnc_alias_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: IL-7,IL-8,IL-23
  symbol: IL-23
  source: hgnc_alias_symbol
  hgnc_symbol: IL23A
  entrez: '51561'
- word: IL-7,IL-8,IL-23
  symbol: IL-8
  source: hgnc_alias_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: IL-7,IL-8,IL-23
  symbol: IL-7
  source: hgnc_alias_symbol
  hgnc_symbol: IL7
  entrez: '3574'
- word: IL-7,
  symbol: IL-7
  source: hgnc_alias_symbol
  hgnc_symbol: IL7
  entrez: '3574'
- word: ÐžPG
  symbol: OPG
  source: hgnc_prev_symbol
  hgnc_symbol: TNFRSF11B
  entrez: '4982'
- word: Rankl
  symbol: RANKL
  source: hgnc_alias_symbol
  hgnc_symbol: TNFSF11
  entrez: '8600'
- word: IL-8
  symbol: IL-8
  source: hgnc_alias_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: IL-6,
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: PTHPP,IL-1,IL-6,IL-8
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: PTHPP,IL-1,IL-6,IL-8
  symbol: IL-8
  source: hgnc_alias_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: PTHPP,IL-1,IL-6,IL-8
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1A
  entrez: '3552'
- word: PTHPP,IL-1,IL-6,IL-8
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: IL-1,
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1A
  entrez: '3552'
- word: IL-1,
  symbol: IL1
  source: bioentities_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
chemicals:
- word: Zoledronic acid
  source: MESH
  identifier: C088658
diseases: []
---
